Search

Your search keyword '"Fouque D"' showing total 901 results
Start Over Author "Fouque D"
901 results on '"Fouque D"'

1. Erratum

Author

Slee, A, McKeaveney, C, Adamson, G, Davenport, A, Far-Rington, K, Fouque, D, Kalantar-Zadeh, K, Mallett, J, Maxwell, AP, Mullan, R, Noble, H, O'Donoghue, D, Porter, S, Seres, DS, Shields, J, Witham, M, and Reid, J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Nutrition and Dietetics, Urology & Nephrology, Clinical sciences, Nutrition and dietetics
Published
2021

5. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.

Author

Fouque, D, Kalantar-Zadeh, K, Kopple, J, Cano, N, Chauveau, P, Cuppari, L, Franch, H, Guarnieri, G, Ikizler, TA, Kaysen, G, Lindholm, B, Massy, Z, Mitch, W, Pineda, E, Stenvinkel, P, Treviño-Becerra, A, and Wanner, C

Subjects
Humans, Kidney Diseases, Wasting Syndrome, Malnutrition, Syndrome, Acute Disease, Chronic Disease, Inflammation, Cachexia, Proteins, Energy Metabolism, Terminology as Topic, malnutrition, inflammation, protein-energy wasting, cachexia, kidney disease wasting, anorexia, Urology & Nephrology, Clinical Sciences
Abstract

The recent research findings concerning syndromes of muscle wasting, malnutrition, and inflammation in individuals with chronic kidney disease (CKD) or acute kidney injury (AKI) have led to a need for new terminology. To address this need, the International Society of Renal Nutrition and Metabolism (ISRNM) convened an expert panel to review and develop standard terminologies and definitions related to wasting, cachexia, malnutrition, and inflammation in CKD and AKI. The ISRNM expert panel recommends the term 'protein-energy wasting' for loss of body protein mass and fuel reserves. 'Kidney disease wasting' refers to the occurrence of protein-energy wasting in CKD or AKI regardless of the cause. Cachexia is a severe form of protein-energy wasting that occurs infrequently in kidney disease. Protein-energy wasting is diagnosed if three characteristics are present (low serum levels of albumin, transthyretin, or cholesterol), reduced body mass (low or reduced body or fat mass or weight loss with reduced intake of protein and energy), and reduced muscle mass (muscle wasting or sarcopenia, reduced mid-arm muscle circumference). The kidney disease wasting is divided into two main categories of CKD- and AKI-associated protein-energy wasting. Measures of chronic inflammation or other developing tests can be useful clues for the existence of protein-energy wasting but do not define protein-energy wasting. Clinical staging and potential treatment strategies for protein-energy wasting are to be developed in the future.

Published
2008

13. Evolution du profil cognitive des patients ayant une maladie rénale chronique : étude longitudinale de la cohorte CKD REIN

Author

Levassort, H., primary, Pépin, M., additional, Boucquemont, J., additional, Lambert, O., additional, Alencar De Pinho, N., additional, Turinici, M., additional, Helmer, C., additional, Metzger, M., additional, Teillet, L., additional, Frimat, L., additional, Combe, C., additional, Fouque, D., additional, Laville, M., additional, Ayav, C., additional, and Jacquelinet, C., additional

Published
2022
Full Text
View/download PDF

15. Brain dysfunction in tubular and tubulointerstitial kidney diseases

Author

Viggiano D, Bruchfeld A, Carriazo S, de Donato A, Endlich N, Ferreira AC, Figurek A, Fouque D, Franssen CFM, Giannakou K, Goumenos D, Hoorn EJ, Nitsch D, Arduan AO, Pešić V, Rastenyté D, Soler MJ, Rroji M, Trepiccione F, Unwin RJ, Wagner CA, Wiecek A, Zacchia M, Zoccali C, Capasso G, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)., Viggiano, D, Bruchfeld, A, Carriazo, S, de Donato, A, Endlich, N, Ferreira, Ac, Figurek, A, Fouque, D, Franssen, Cfm, Giannakou, K, Goumenos, D, Hoorn, Ej, Nitsch, D, Arduan, Ao, Pešić, V, Rastenyté, D, Soler, Mj, Rroji, M, Trepiccione, F, Unwin, Rj, Wagner, Ca, Wiecek, A, Zacchia, M, Zoccali, C, Capasso, G, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative, Target)., NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), CarMeN, laboratoire, University of the Study of Campania Luigi Vanvitelli, Karolinska University Hospital [Stockholm], Linköping University (LIU), IIS‑Fundación Jiménez Diaz‑Autonoma University [Madrid, Spain], University of Medicine Greifswald, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Universität Zürich [Zürich] = University of Zurich (UZH), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), University of Groningen [Groningen], European University of Cyprus, General University Hospital of Patras, Erasmus University Medical Center [Rotterdam] (Erasmus MC), London School of Hygiene and Tropical Medicine (LSHTM), University of Belgrade [Belgrade], Lithuanian University of health Sciences [Kaunas], Vall d’Hebron Research Institute (VHIR), University Hospital Center 'Mother Tereza' [Tirana, Albania] (UHCMT), University College of London [London] (UCL), Medical University of Silesia (SUM), Renal Research Institute [New York, NY, USA] (2RI), CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target): Giovambattista Capasso, Alexandre Andrade, Maie Bachmann, Inga Bumblyte, Adrian Constantin Covic, Pilar Delgado, Nicole Endlich, Andreas Engvig, Denis Fouque, Casper Franssen, Sebastian Frische, Liliana Garneata, Loreto Gesualdo, Konstantinos Giannakou, Dimitrios Goumenos, Ayşe Tuğba Kartal, Laila-Yasmin Mani, Hans-Peter Marti, Christopher Mayer, Rikke Nielsen, Vesna Pšić, Merita Rroji Molla, Giorgos Sakkas, Goce Spasovski, Kate I Stevens, Evgueniy Vazelov, Davide Viggiano, Lefteris Zacharia, Ana Carina Ferreira, Jolanta Malyszko, Ewout Hoorn, Andreja Figurek, Robert Unwin, Carsten A Wagner, Christoph Wanner, Annette Bruchfeld, Marion Pépin, Andrzej Wieçek, Dorothea Nitsch, Ivo Fridolin, Gaye Hafez, Maria José Soler, Michelangela Barbieri, Bojan Batinić, Laura Carrasco, Sol Carriazo, Ron Gansevoort, Gianvito Martino, Francesco Mattace Raso, Ionut Nistor, Alberto Ortiz, Giuseppe Paolisso, Daiva Rastenytė, Gabriel Stefan, Gioacchino Tedeschi, Ziad A Massy, Boris Bikbov, Karl Hans Endlich, Olivier Godefroy, Jean-Marc Chillon, Anastassia Kossioni, Justina Kurganaite, Norberto Perico, Giuseppe Remuzzi, Tomasz Grodzicki, Francesco Trepiccione, Carmine Zoccali, Mustafa Arici, Peter Blankestijn, Kai-Uwe Eckardt, Danilo Fliser, Eugenio Gutiérrez Jiménez, Maximilian König, Ivan Rychlik, Michela Deleidi, George Reusz, and Internal Medicine

Subjects
ACIDOSIS, [SDV]Life Sciences [q-bio], Review, Disease, electrolyte, 030204 cardiovascular system & hematology, urologic and male genital diseases, 0302 clinical medicine, Child, 610 Medicine & health, MUTATION, 0303 health sciences, Kidney, Proteinuria, Reabsorption, female genital diseases and pregnancy complications, 3. Good health, [SDV] Life Sciences [q-bio], BARTTER-SYNDROME, medicine.anatomical_structure, Nephrology, Child, Preschool, GITELMANS-SYNDROME, Kidney Diseases, medicine.symptom, Glomerular Filtration Rate, medicine.medical_specialty, brain, chronic kidney disease, cognitive function, tubulointerstitial, Urology, Renal function, 03 medical and health sciences, SDG 3 - Good Health and Well-being, medicine, Humans, Renal Insufficiency, Chronic, AcademicSubjects/MED00340, NEPHRITIS, 030304 developmental biology, Rheumatology and Autoimmunity, Transplantation, Reumatologi och inflammation, HYPONATREMIA, business.industry, urogenital system, AQP2, medicine.disease, Nephrogenic diabetes insipidus, GENE, KLOTHO, MODEL, Nephritis, Interstitial, business, Tubulointerstitial Disease, Kidney disease
Abstract

Funding: This article is published as part of a supplement financially supported by the COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT). Kidney function has two important elements: glomerular filtration and tubular function (secretion and reabsorption). A persistent decrease in glomerular filtration rate (GFR), with or without proteinuria, is diagnostic of chronic kidney disease (CKD). While glomerular injury or disease is a major cause of CKD and usually associated with proteinuria, predominant tubular injury, with or without tubulointerstitial disease, is typically non-proteinuric. CKD has been linked with cognitive impairment, but it is unclear how much this depends on a decreased GFR, altered tubular function or the presence of proteinuria. Since CKD is often accompanied by tubular and interstitial dysfunction, we explore here for the first time the potential role of the tubular and tubulointerstitial compartments in cognitive dysfunction. To help address this issue we selected a group of primary tubular diseases with preserved GFR in which to review the evidence for any association with brain dysfunction. Cognition, mood, neurosensory and motor disturbances are not well characterized in tubular diseases, possibly because they are subclinical and less prominent than other clinical manifestations. The available literature suggests that brain dysfunction in tubular and tubulointerstitial diseases is usually mild and is more often seen in disorders of water handling. Brain dysfunction may occur when severe electrolyte and water disorders in young children persist over a long period of time before the diagnosis is made. We have chosen Bartter and Gitelman syndromes and nephrogenic diabetes insipidus as examples to highlight this topic. We discuss current published findings, some unanswered questions and propose topics for future research. publishersversion published

Published
2022
Full Text
View/download PDF

28. Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

Author

Goldsmith, David, Covic, Adrian, Vervloet, Marc, Cozzolino, Mario, Nistor, Ionut, Cozzolino, Mario, Vervloet, Mark, Brandenburg, Vincent, Bover, Jordi, Covic, Adrian, Evenepoel, Pieter, Goldsmith, David, Massy, Ziad, Mazzaferro, Sandro, Urena-Torres, Pablo, Abramowicz, D., Bolignano, D., Cannata Andia, G., Cochat, P., Covic, A., Delvecchio, L., Drechsler, C., Eckardt, K.U., Fouque, D., Fox, J., Haller, M., Heimburger, O., Jager, K.J., Lindley, E., Marti Monros, A.M., Nagler, E., Oberbauer, R., Spasovski, G., Tattersall, J., Van Biesen, W., vander Veer, S., Vanholder, R., Wanner, C., Wheeler, D., Whithers, W., Wiecek, A., and Zoccali, C.

Published
2015
Full Text
View/download PDF

30. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Author

Ortiz, A, Cozzolino, M, Duivenvoorden, R, Fliser, D, Fouque, D, Franssen, CFM, Goumenos, D, Hemmelder, MH, Hilbrands, LB, Jager, KJ, Massy, ZA, Noordzij, M, Rosenkranz, AR, Rychlik, I, Soler, MJ, Stevens, K, Torra, R, Tuglular, S, Vart, P, Wanner, C, Gansevoort, RT, ERA-EDTA Council, and Eracoda Working Grp

Subjects
risk factor, prevalence, COVID-19, mortality, renal replacement therapy, chronic kidney disease
Abstract

Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR

Published
2021

31. Erratum to: Using a generic definition of cachexia to understand clinical characteristics and mortality in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study

Author

Mckeaveney, C., Slee, A., Adamson, G., Davenport, A., Farrington, K., Fouque, D., Kalanter-Zadeh, K., Mallett, J., Maxwell, A. P., Mullan, R., Noble, H., O'Donoghue, D., Porter, S., Seres, D. S., Shields, J., Witham, M., Reid, J., University College of London [London] (UCL), University of Ulster, School of Metallurgy and Materials, University of Birmingham [Birmingham], University of Hertfordshire [Hatfield] (UH), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of California [Irvine] (UCI), University of California, Royal Victoria Hospital [Belfast, UK], Queen's University [Belfast] (QUB), Belfast City Hospital, Antrim Area Hospital - Northern Health and Social Care Trust [Antrim, Northern Ireland] (AAH-NHSCT), University of Manchester [Manchester], Bournemouth University [Poole] (BU), New York Presbyterian Hospital, Newcastle University [Newcastle], University of California [Irvine] (UC Irvine), University of California (UC), and CarMeN, laboratoire

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2021
Full Text
View/download PDF

32. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

Author

Ortiz, A., Cozzolino, M., Duivenvoorden, R., Fliser, D., Fouque, D., Franssen, C.F., Goumenos, D., Hemmelder, M.H., Hilbrands, L.B., Jager, K.J., Massy, Z.A., Noordzij, Marlies, Rosenkranz, A., Rychlık, I., Soler, M.J., Stevens, K., Torra, R., Tuglular, S., Vart, P., Wanner, C., Gansevoort, R.T., Ortiz, A., Cozzolino, M., Duivenvoorden, R., Fliser, D., Fouque, D., Franssen, C.F., Goumenos, D., Hemmelder, M.H., Hilbrands, L.B., Jager, K.J., Massy, Z.A., Noordzij, Marlies, Rosenkranz, A., Rychlık, I., Soler, M.J., Stevens, K., Torra, R., Tuglular, S., Vart, P., Wanner, C., and Gansevoort, R.T.

Abstract

Contains fulltext : 232029.pdf (Publisher’s version ) (Open Access)

Published
2021

36. Plant-based diets to manage the risks and complications of chronic kidney disease

Author

Carrero JJ, González-Ortiz A, Avesani CM, Bakker SJL, Bellizzi V, Chauveau P, Clase CM, Cupisti A, Espinosa-Cuevas A, Molina P, Moreau K, Piccoli GB, Post A, Sezer S, and Fouque D

Subjects
food and beverages
Abstract

Traditional dietary recommendations for patients with chronic kidney disease (CKD) focus on the quantity of nutrients consumed. Without appropriate dietary counselling, these restrictions can result in a low intake of fruits and vegetables and a lack of diversity in the diet. Plant nutrients and plant-based diets could have beneficial effects in patients with CKD: increased fibre intake shifts the gut microbiota towards reduced production of uraemic toxins; plant fats, particularly olive oil, have anti-atherogenic effects; plant anions might mitigate metabolic acidosis and slow CKD progression; and as plant phosphorus has a lower bioavailability than animal phosphorus, plant-based diets might enable better control of hyperphosphataemia. Current evidence suggests that promoting the adoption of plant-based diets has few risks but potential benefits for the primary prevention of CKD, as well as for delaying progression in patients with CKD G3-5. These diets might also help to manage and prevent some of the symptoms and metabolic complications of CKD. We suggest that restriction of plant foods as a strategy to prevent hyperkalaemia or undernutrition should be individualized to avoid depriving patients with CKD of these potential beneficial effects of plant-based diets. However, research is needed to address knowledge gaps, particularly regarding the relevance and extent of diet-induced hyperkalaemia in patients undergoing dialysis. Emerging evidence suggests that plant-based diets could help to prevent chronic kidney disease (CKD), manage its symptoms and metabolic complications and delay disease progression. Here, the authors discuss the potential risks and benefits of these diets in patients with CKD, as well as implementation strategies and knowledge gaps.

Published
2020

37. Mild cognitive impairment and kidney disease: clinical aspects

Author

Viggiano, D. (Davide), Wagner, C.A. (Carsten), Blankestijn, P.J. (Peter), Bruchfeld, A. (Annette), Fliser, D. (Danilo), Fouque, D. (Denis), Frische, S. (Sebastian), Gesualdo, L. (Loreto), Gutiérrez, E. (Eugenio), Goumenos, D. (Dimitrios), Hoorn, E.J. (Ewout), Eckardt, K.-U. (Kai-Uwe), Knauß, S. (Samuel), König, M. (Maximilian), Malyszko, J. (Jolanta), Massy, Z. (Ziad), Nitsch, R. (Robert), Pesce, F. (Francesco), Rychlík, I. (Ivan), Soler, M.J. (Maria Jose), Spasovski, G. (Goce), Stevens, K.I. (Kathryn I.), Trepiccione, F. (Francesco), Wanner, C. (Christoph), Wiecek, A. (Andrzej), Zoccali, C. (Carmine), Unwin, R.J. (Robert John), Capasso, G. (Giovambattista), Viggiano, D. (Davide), Wagner, C.A. (Carsten), Blankestijn, P.J. (Peter), Bruchfeld, A. (Annette), Fliser, D. (Danilo), Fouque, D. (Denis), Frische, S. (Sebastian), Gesualdo, L. (Loreto), Gutiérrez, E. (Eugenio), Goumenos, D. (Dimitrios), Hoorn, E.J. (Ewout), Eckardt, K.-U. (Kai-Uwe), Knauß, S. (Samuel), König, M. (Maximilian), Malyszko, J. (Jolanta), Massy, Z. (Ziad), Nitsch, R. (Robert), Pesce, F. (Francesco), Rychlík, I. (Ivan), Soler, M.J. (Maria Jose), Spasovski, G. (Goce), Stevens, K.I. (Kathryn I.), Trepiccione, F. (Francesco), Wanner, C. (Christoph), Wiecek, A. (Andrzej), Zoccali, C. (Carmine), Unwin, R.J. (Robert John), and Capasso, G. (Giovambattista)

Published
2020
Full Text
View/download PDF

38. Mild cognitive impairment and kidney disease: clinical aspects

Author

Viggiano, D, Wagner, CA, Blankestijn, PJ, Bruchfeld, A, Fliser, D, Fouque, D, Frische, S, Gesualdo, L, Gutierrez, E, Goumenos, D, Hoorn, Ewout, Eckardt, KU, Knauss, S, Konig, M, Malyszko, J, Massy, Z, Nitsch, D, Pesce, F, Rychlik, I, Soler, MJ, Spasovski, G, Stevens, KI, Trepiccione, F, Wanner, C, Wiecek, A, Zoccali, C, Unwin, R, Capasso, G, Viggiano, D, Wagner, CA, Blankestijn, PJ, Bruchfeld, A, Fliser, D, Fouque, D, Frische, S, Gesualdo, L, Gutierrez, E, Goumenos, D, Hoorn, Ewout, Eckardt, KU, Knauss, S, Konig, M, Malyszko, J, Massy, Z, Nitsch, D, Pesce, F, Rychlik, I, Soler, MJ, Spasovski, G, Stevens, KI, Trepiccione, F, Wanner, C, Wiecek, A, Zoccali, C, Unwin, R, and Capasso, G

Published
2020

41. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Author

Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R. R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nürnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N. S., Trivelli, A., Zimmerhackl, L. B., Goodship, T., and Loirat, C.

Published
2013
Full Text
View/download PDF

42. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement

Author

Locatelli, Francesco, Bárány, Peter, Covic, Adrian, De Francisco, Angel, Del Vecchio, Lucia, Goldsmith, David, Hörl, Walter, London, Gerard, Vanholder, Raymond, Van Biesen, Wim, Abramovicz, D., Cannata-Andia, J., Cochat, P., Eckardt, K. U., Fouque, D., Heimburger, O., Jäger, K., Jenkins, S., Lindley, E., MacLeod, A., Marti-Monros, A., Tattersall, J., Wiecek, A., and Wanner, C.

Published
2013
Full Text
View/download PDF

49. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine

Author

Capasso, A., Benigni, A., Capitanio, U., Danesh, F. R., Di Marzo, V., Gesualdo, L., Grandaliano, Giuseppe, Jaimes, E. A., Malyszko, J., Perazella, M. A., Qian, Q., Ronco, P., Rosner, M. H., Trepiccione, F., Viggiano, D., Zoccali, C., Capasso, G., Akitaka, A., Alahoti, A., Alexander, T. R., Altucci, L., Amer, H., Barone, V., Biancone, L., Bonventre, J. V., Camussi, G., Ciardiello, F., Caraglia, M., Carteni, G., Cervantes, A., Citterio, Franco, Cosmai, L., Daniele, B., D'Errico, A., De Vita, F., Ereditato, A., Falco, G., Fouque, D., Franco, R., Gallieni, M., Gambaro, G., Kuo, C., Launay-Vacher, V., Maiello, E., Mallamaci, F., Malysxko, J., Marino, G., Martinelli, E., Matarese, G., Matsubara, T., Messa, P., Messina, C., Mirone, V., Morgillo, F., Costa, A. N., Orditura, M., Pani, A., Perna, A., Pisano, C., Pitts, T., Porta, C., Procopio, G., Remuzzi, G., Russo, D., Siu, L. L., Stadler, W., Troiani, T., Weisz, A., Wiecek, A., Xiaoqiang, D., Zecchino, O., Grandaliano G. (ORCID:0000-0003-1213-2177), Citterio F. (ORCID:0000-0003-0489-6337), Capasso, A., Benigni, A., Capitanio, U., Danesh, F. R., Di Marzo, V., Gesualdo, L., Grandaliano, Giuseppe, Jaimes, E. A., Malyszko, J., Perazella, M. A., Qian, Q., Ronco, P., Rosner, M. H., Trepiccione, F., Viggiano, D., Zoccali, C., Capasso, G., Akitaka, A., Alahoti, A., Alexander, T. R., Altucci, L., Amer, H., Barone, V., Biancone, L., Bonventre, J. V., Camussi, G., Ciardiello, F., Caraglia, M., Carteni, G., Cervantes, A., Citterio, Franco, Cosmai, L., Daniele, B., D'Errico, A., De Vita, F., Ereditato, A., Falco, G., Fouque, D., Franco, R., Gallieni, M., Gambaro, G., Kuo, C., Launay-Vacher, V., Maiello, E., Mallamaci, F., Malysxko, J., Marino, G., Martinelli, E., Matarese, G., Matsubara, T., Messa, P., Messina, C., Mirone, V., Morgillo, F., Costa, A. N., Orditura, M., Pani, A., Perna, A., Pisano, C., Pitts, T., Porta, C., Procopio, G., Remuzzi, G., Russo, D., Siu, L. L., Stadler, W., Troiani, T., Weisz, A., Wiecek, A., Xiaoqiang, D., Zecchino, O., Grandaliano G. (ORCID:0000-0003-1213-2177), and Citterio F. (ORCID:0000-0003-0489-6337)

Abstract

Onco-nephrology is an emerging field in medicine. Patients with cancer may suffer from kidney diseases because of the cancer itself and cancer-related therapy. It is critical for nephrologists to be knowledgeable of cancer biology and therapy in order to be fully integrated in the multidisciplinary team and optimally manage patients with cancer and kidney diseases. In a recent international meeting, the key issues in this challenging clinical interface were addressed, including many unresolved basic science questions, such as the high tumor incidence in kidney transplant recipients. To this end, 70 highly qualified faculty members were gathered from all over the world to discuss these issues in 8 plenary sessions, including 5 keynote lectures. In addition, 48 young nephrologists and oncologists were invited to present their original observations that were highlighted in 2 large poster sessions.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results